HB 134 – Maryland

Status: Inactive / Dead
Year Introduced: 2020
Link: http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB0134?ys=2020RS

Health Insurance – Prescription Insulin Drugs – Limits on Copayment and Coinsurance. Requiring certain insurers, nonprofit health service plans, and health maintenance organizations to limit the cumulative amount a covered individual is required to pay on copayment or coinsurance for a covered prescription insulin drug to no more than $100, regardless of the amount or type of insulin needed to fill the covered individual’s prescriptions; applying the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2021; etc.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found